Inovio Pharmaceuticals, Inc. Common Stock INO
i
Market dataready · fetched 2026-11-10T22:19:45.112Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T22:19:36.757262627Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-10T22:19:43.890687+00:00
Inovio Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 1.74 | 327.0% | 36.0% | |||
| 30Δ | 1.64 | 312.2% | 28.6% | |||
| 35Δ | 1.53 | 297.4% | 21.2% | |||
| 40Δ | 1.45 | 331.1% | 18.6% | |||
| 45Δ | 1.39 | 381.3% | 17.7% | |||
| 50Δ | 1.33 | 431.4% | 16.8% | |||
| 55Δ | 1.27 | 481.5% | 15.9% | |||
| 60Δ | 1.21 | 531.7% | 15.0% | |||
| 65Δ | 1.15 | 581.8% | 14.0% | |||
| 70Δ | 1.09 | 632.0% | 13.1% | |||
| 75Δ | 1.03 | 682.1% | 12.2% | |||
| 80Δ | 0.93 | 719.9% | 11.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 1.74
- IV
- 327.0%
- B/E move
- 36.0%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 1.64
- IV
- 312.2%
- B/E move
- 28.6%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 1.53
- IV
- 297.4%
- B/E move
- 21.2%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 1.45
- IV
- 331.1%
- B/E move
- 18.6%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 1.39
- IV
- 381.3%
- B/E move
- 17.7%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 1.33
- IV
- 431.4%
- B/E move
- 16.8%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 1.27
- IV
- 481.5%
- B/E move
- 15.9%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 1.21
- IV
- 531.7%
- B/E move
- 15.0%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 1.15
- IV
- 581.8%
- B/E move
- 14.0%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 1.09
- IV
- 632.0%
- B/E move
- 13.1%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 1.03
- IV
- 682.1%
- B/E move
- 12.2%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 0.93
- IV
- 719.9%
- B/E move
- 11.5%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 532.04% | |
| 520.79% |
Biotechnology
INSM
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New…
More →INVA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
More →IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
More →IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's…
More →IPSC
Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging…
More →IRD
Description unavailable
More →